Article info

Download PDFPDF

Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?
Free

Authors

  1. Correspondence to Professor Gabriel Herrero-Beaumont, Rheumatology, Fundacion Jimenez Diaz, 28040 Madrid, Spain; gherrero{at}fjd.es
View Full Text

Citation

Herrero-Beaumont G, Largo R
Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?

Publication history

  • Received May 21, 2020
  • Revised June 3, 2020
  • Accepted June 4, 2020
  • First published June 18, 2020.
Online issue publication 
September 14, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.